You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Bruker's system has seen strong uptake among proteomics researchers, but its ability to generate large amounts of complex data has led to analysis challenges.
The firm's predicted Q2 revenues of $517 million to $523 million beat expectations as former MilliporeSigma CEO Udit Batra becomes president and CEO.
The platform combines Leica's laser microdissection tool and PBI's pressure cycling tech to enable better extraction and digestion of proteins from biopsies.
The work suggests mass spec can more accurately assess levels of immunotherapy targets like PD-L1 than conventional clinical approaches.
The researchers covered 100 organisms from a wide range of taxonomies, allowing for large-scale cross comparisons of species at the protein level.
While there were a few new mass spectrometry instrument introductions, vendors focused primarily on software and sample separation advances.
Researchers used a high-throughput proteomic platform to find patterns of protein expression that could identify patients at risk of developing severe infections.
The company is developing a mass spec-based instrument for the detection and identification of airborne opioids, microbes, and toxins in real-time.
The companies aim to develop robust methods for experiments analyzing thousands of tissue and plasma proteomes.
The company said it will use the two-year grant to optimize its LC manufacturing process and development new chromatography products.
The approach is essentially a simplified version of the technology in Fluidigm's CyTOF instruments, using metal-linked antibodies to measure proteins.
The company is working with German informatics firm MSAID to incorporate deep learning into mass spec analysis and with Biognosys on tools for quantitative work.
The firm said total revenues fell to $424.0 million from $461.4 million in the first quarter of 2019, below analysts' consensus estimate of $444.4 million.
Waters posted revenues of $464.9 million for the quarter as the SARS-CoV-2 pandemic drove a drop in sales globally, including a 45 percent decline in China.
The team, which was led by founders of the mass spec firm Purspec, demonstrated the ability of the instrument to quantify levels of the cancer marker Met.
The firm delayed reporting final results due to questions of accounting irregularities but found no misconduct and made no changes to its preliminary results.
The last week has seen several COVID-19 publications from proteomics groups as the field explores what it can add to drug and diagnostics development.
Researchers at the laboratory have developed a single-cell proteomics workflow capable of reproducibly quantifying 1,000-plus proteins per cell.
Multi-omics approaches can give insight into the gut microbiome and more, but there are still challenges to address, speakers at the ABRF meeting said.
The method could prove useful for applications like single-cell proteomics where datasets often have small numbers of high-quality peptide identifications.
The Washington Post reports that US states and territories are seeking more funding for the distribution of SARS-CoV-2 vaccines.
The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.
A new study suggests that using CRISPR to edit human embryonic DNA can lead to the loss of whole chromosomes, as the Associated Press reports.
In Science this week: ancient dog genomes highlight long ties with humans, genomic analysis of 40,000-year-old early East Asian individual, and more.